Intermittent versus continuous erlotinib with concomitant modified “XELOX” (q3W) in first‐line treatment of metastatic colorectal cancer

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|23|4145-4153

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.23, 2013-12, pp. : 4145-4153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

By  

Oncology, Vol. 79, Iss. 3-4, 2011-02 ,pp. : 174-180

Karger

Access to resources Recommend Favorite

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4290-4298

John Wiley & Sons Inc

Access to resources Recommend Favorite

First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer

By  

Oncology, Vol. 68, Iss. 1, 2005-04 ,pp. : 58-63

Karger

Access to resources Recommend Favorite

Use and impact of intermittent versus continuous systemic treatment strategies in metastatic colorectal cancer in routine practice

By  

CANCER, Vol. 121, Iss. 16, 2015-08 ,pp. : 2791-2798

John Wiley & Sons Inc

Access to resources Recommend Favorite

Oxaliplatin, Irinotecan and Capecitabine (OCX) for First-Line Treatment of Advanced/Metastatic Colorectal Cancer: A Phase I Trial (SAKK 41/03)

By  

Oncology Research and Treatment, Vol. 33, Iss. 6, 2010-05 ,pp. : 295-299

Karger

Access to resources Recommend Favorite